Navigation Links
Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
Date:2/11/2009

PALO ALTO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs. The reorganization will enable the company to continue the development of TELINTRA(R) and the two leading preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404.

The restructuring will involve a workforce reduction of 44% primarily in early-stage discovery and support positions. Employees directly affected by the restructuring plan will receive severance payments, continuation of benefits and outplacement assistance. The company estimates incurring personnel-related restructuring charges of approximately $0.9 million in the first quarter of 2009.

"This reorganization will allow us to focus our resources on the clinical development of our lead compound, TELINTRA, currently in Phase 2 Studies for Myleodysplastic Syndrome and Chemotherapy Induced Neutropenia, as well as other potential indications. We also plan to advance our two leading preclinical drug candidates and continue to support our TRAP(R) technology collaborations," said Michael Wick, M.D., Ph.D., Chairman and Chief Executive Officer. "We are thankful for the significant contributions our employees have made."

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including but not limited to statements with respect to the amount and timing of expected restructuring charges relating to the reorganization plan, and the continuing development of TELINTRA and preclinical drug candidates. Any statements herein that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including, among others, risks and uncertainties related to Telik's ability to obtain the capital necessary to fund its continuing operations on acceptable terms or to enter into a third party collaboration to develop, manufacture and commercialize our products, the possibility that the Company may require more cash than anticipated for its operating activities, the Company's need to retain skilled employees and consultants, and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, and other periodic filings with the SEC. The Company does not undertake any obligation to update forward-looking statements.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces New TRAP Drug Discovery Agreement
2. Telik Announces Financial Results for 2008 Third Quarter
3. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
4. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
5. Telik Announces Receipt of Nasdaq Notice
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. ReceptorBio Announces Diabetes License Agreement With Telik
8. Telik Announces Financial Results For 2008 Second Quarter
9. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):